Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: A systematic review and meta-analysis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 7-8, 2011, Pages 237-246

  Szypowska, Agnieszka ^a   Golicki, Dominik ^a   Groele, Lidia ^a   Pańkowska, Ewa ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

Basal bolus therapy; Detemir; Fasting plasma glucose; NPH insulin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; ISOPHANE INSULIN;

ARTICLE; DIABETES CONTROL; DRUG EFFICACY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; META ANALYSIS; SYSTEMATIC REVIEW; WEIGHT GAIN;

EID: 80052365247     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1065     Document Type: Article

References (51)

1. Wang P.H., Lau J., Chalmers T.C. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet. 1993; 341: 1306-1309. (Pubitemid 23148093)
2. Krzymień J., Kobli T., Nazar M. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes. Pol Arch Med Wewn. 2010; 120: 444-450.
3. Kølendorf K., Bojse J., Deckert T. Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients. Horm Metab Res. 1983; 15: 274-278. (Pubitemid 13056580)
4. Starke A., Heinemann L., Hohlmann A., Berger M. The action profiles of human NPH insulin preparations. Diabet Med. 1983; 6: 239-244.
5. Diabetes Control and Complications Trial Research Group. Hypoglycaemia in the Diabetes Control and Complications Trial. Diabetes. 1997; 46: 271-286.
6. Diabetes Control and Complications Trial Research Group. Weight gain associated with intensive therapy in the diabetes control and complication trial. Diabetes Care. 1988; 11: 567-573.
7. Raslova K. An update on the treatment of type 1 and type 2 diabetes mellitus: Focus on insulin detemir, a long-acting human insulin analog. Vasc Health Risk Manag. 2010; 6: 399-410.
8. Whittingham J.L., Havelund S., Jonassen I. Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry. 1997; 36: 2826-2831. (Pubitemid 27138564)
9. Havelund S., Plum A., Ribel U., et al. The mechanisms of protraction of insulin detemir, a long acting, acylated analog of human insulin. Pharm Res. 2004; 21: 1498-1504. (Pubitemid 39149667)
10. Danne T., Lüpke K., Walte K., et al. Insulin detemir is characterized by a consistent pharmacokinetic profile cross age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003; 26: 3087-3092. (Pubitemid 37339503)
11. Heise T., Nosek L., Rønn B.B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53: 1614-1620. (Pubitemid 38697678)
12. Porcellati F., Rossetti P., Busciantella N.R., et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care. 2007; 30: 2447-2452. (Pubitemid 47547770)
13. Kato T., Tokubuchi I., Muraishi K., et al. Distinct pharmacodynamics of insulin glargine and insulin detemir: Crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen. Diabetes Res Clin Pract. 2010; 90: e64-e66
14. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004; 47: 622-629. (Pubitemid 38658363)
15. Hermansen K., Madsbad S., Perrild H., et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care. 2001; 24: 296-301. (Pubitemid 32119128)
16. Porcellati F., Rossetti P., Pampanelli S., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004; 21: 1213-1220. (Pubitemid 39472377)
17. Standl E., Lang H., Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther. 20 004; 6: 579-588.
18. De Leeuw I., Vague P., Selam J.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005; 7: 73-82.
19. Home P.D., Rosskamp R., Forjanic-Klapproth J., Dressler A.; European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev. 2005; 21: 545-553. (Pubitemid 41646014)
20. Monami M., Marchionni N., Manucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. Diabetes Obes Metab. 2009; 11: 372-378.
21. Hartman I. Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008; 6: 54-67.
22. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions 4.2.6 (updated September 2006). The Cochrane Library, Issue 2. Wiley, Chichester; 2007.
23. Homa K., Majkowska L. Difficulties in interpreting HbA(1c) results. Pol Arch Med Wewn. 2010; 120: 148-154.
24. Bartley P.C., Bogoev M., Larsen J., Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: A 2-year, randomized, controlled trial. Diabet Med. 2008; 25: 442-449. (Pubitemid 351490120)
25. Kølendorf K., Ross G.P., Pavlic-Renar I., et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med. 2006; 23: 729-735. (Pubitemid 44366070)
26. Pieber T.R., Draeger E., Kristensen A., Grill V. Comparison of three multiple injection regimens for type 1 diabetes: Morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005; 22: 850-857. (Pubitemid 40942581)
27. Robertson K.J., Schoenle E., Gucev Z., et al. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med. 2007; 24: 27-34. (Pubitemid 46103068)
28. Russell-Jones D., Simpson R., Hylleberg B., et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004; 26: 724-736. (Pubitemid 38736962)
29. Vague P., Jean-Louis S., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003; 26: 590-596. (Pubitemid 36929312)
30. Home P., Bartley P., Russell-Jones D., et al.; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Study to Evaluate the administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group (2004) Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care. 2004; 27: 1081-1087.
31. Trial NN304-1604. Integrated Clinical Trial Report. http://novonordisk- trials.com/website/pdf/registry/bin-20 070614-125633-724.pdf.
32. Trial NN304-1689. Clinical Trial Report. http://novonordisk-trials.com/ website/pdf/registry/bin-20090818-082619-197.pdf.
33. Trial NN304-1476. Integrated Clinical Trial Report. http://novonordisk- trials.com/website/pdf/registry/bin-20070524-020347-264.pdf.
34. Sumník Z., Venhácová J., Brázdová L., Skvor J. [Long-term improvement of fasting glycaemia after switching basal insulin from NPH to determir in children with type 1 diabetes: a 1-year multicentre study]. Cas Lek Cesk. 2008; 147: 421-425. Czech.
35. Braun D., Konrad D., Lang-Muritano M., Schoenle E. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes. Pediatr Diabetes. 2008; 9: 382-387.
36. Wutte A., Plank J., Bodenlenz M., et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007; 115: 461-467. (Pubitemid 47234648)
37. Bott S., Tusek C., Jacobsen L.V., et al. Insulin detemir under steady-state conditions: No accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabet Med. 2006; 23: 522-528.
38. Palmer A.J., Roze S., Valentine W.J., et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: An economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin. 2004; 20: 1729-1746. (Pubitemid 39611932)
39. Dornhorst A., Lüddeke H.J., Honka M., et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin. 2008; 24: 369-376. (Pubitemid 351294387)
40. Pieber T.R., Treichel H.C., Hompesch B., et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med. 2007; 24: 635-642. (Pubitemid 46808860)
41. Danne T., Datz N., Endahl L., et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: Results from a randomized, double-blind, controlled trial. Pediatr Diabetes. 2008; 9: 554-560.
42. Unpublished trial NN304-1582. http://novonordisk-trials.com/website/pdf/ registry/bin-20080115-011953-905.pdf.
43. Standl E., Roberts A., Lang H., Draeger E. Long-term efficacy and safety of insulin detemir in subjects with type 1 diabetes. Favorable weight development and risk reduction of nocturnal hypoglycemia [abstract]. Diabetes. 2002; 51: A115.
44. Russell-Jones D., Bolinder J., Simpson R. Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with Type 1 diabetes. Diabetologia. 2002; 45: A51.
45. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 10; 342: 381-399.
46. Nordwall M., Arnqvist H.J., Bojestig M., Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications -the Linköping Diabetes Complications Study. Pediatr Diabetes. 2009; 10: 168-176.
47. Klein B.E. Progression of retinopathy in persons with type 2 diabetes: New data, same conclusions? Pol Arch Med Wewn. 2010; 120: 413-416.
48. Drzewoski J., Kasznicki J., Trojanowski Z. The role of "metabolic memory"in the natural history of diabetes mellitus. Pol Arch Med Wewn. 2009; 119: 493-500.
49. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329: 977-986.
50. Phillips P.J., Phillipov G. A1c - Frequently asked questions. Aust Fam Physician. 2005; 34: 663-667.
51. Purnell J.Q., Hokanson J.E., Marcovina S.M., et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998; 280: 140-146. (Pubitemid 28498385)